Nightingale Health
2,72
EUR
-2,86 %
Corporate customer
HEALTH
First North Finland
Medical Equipment & Services
Health Care
4.537 følger denne virksomhed
-2,86%
-9,93%
-5,56%
-16,31%
+22,52%
+119,71%
-13,15%
-
-47,18%
Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.
Læs mereMarkedsværdi
165,72 mio. EUR
Aktieomsætning
119,26 t EUR
P/E (adj.) (25e)
-9,78
EV/EBIT (adj.) (25e)
-6,32
P/B (25e)
2,4
EV/S (25e)
17,3
Udbytteafkast, % (25e)
-
Coverage

Head of Nordic ER Development, Analyst
Omsætning og EBIT-margin
Omsætning mio.
EBIT-% (adj.)
EPS og udbytte
EPS (adj.)
Udbytte %
Finanskalender
6.3
2025
Delårsrapport Q2'25
Risiko
Business risk
Valuation risk
Lav
Høj
ViserAlle indholdstyper
Nightingale Health and Enigma Genomics enter into collaboration to sell the Nightingale Remote Health Check in the MENA region
Nightingale Health published new disease risk assessments
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Nightingale Health announces the performance metrics of its latest generation disease risk assessments to be rolled out in Singapore and the United States
Conversion of Nightingale Health Plc's EMP shares to Series B shares
Nightingale Health Plc - Managers' Transactions - Olli Karhi
Nightingale Health Plc appoints Lago Kapital as liquidity provider
Nightingale Health Plc: Subscription of Series B shares with option rights
Study published in Nature Communications: Nightingale Health outperforms genetic testing in chronic disease risk detection and makes the promise of preventative health a reality

Life Science Companies as Investments | Life Science Night Dec. 2, 2024
Nightingale opens Singapore laboratory
Nightingale Health announces opening of its Singapore laboratory
Nightingale explores transfer to Nasdaq Helsinki main list and OTC trading in the US
Inside information: Nightingale Health is investigating the transfer of its B shares to the Main Market of Nasdaq Helsinki and adding the OTCQX market as an additional trading venue in the U.S.
Nightingale completes necessary regulatory approvals in Singapore
Nightingale Health Asia achieves ISO 13485:2016 certification and completes regulatory readiness to launch its blood testing service in Singapore
